Ｅｘｐｒｅｓｓｉｏｎ ａｎｄ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ ｏｆ ＦＢＸＬ２ ａｎｄ Ｄｋｋ⁃１ ｉｎ ｃｏｌｏｒｅｃｔａｌ ｃａｎｃｅｒ Ｌｉ Ｘｉａｏｎｉｎｇ， Ｌｉ Ｘｉａｏｌｏｎｇ∗ ， Ｓｏｎｇ Ｒｕｉ，
Ｚｈａｎｇ Ｈｕｉｑｉｎｇ． ∗ Ｔｈｅ Ｓｅｃｏｎｄ Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｓｕｒｇｅｒｙ， Ｂａｏｄｉｎｇ Ｆｉｒｓｔ Ｃｅｎｔｒａｌ Ｈｏｓｐｉｔａｌ， Ｈｅｂｅｉ Ｐｒｏｖｉｎｃｅ，Ｂａｏｄｉｎｇ ０７１０００，Ｃｈｉｎａ
Ｃｏｒｒｅｓｐｏｎｄｉｎｇ ａｕｔｈｏｒ： Ｚｈａｎｇ Ｈｕｉｑｉｎｇ， Ｅ⁃ｍａｉｌ：ｚｈａｎｇ１３９３１３８６５４２＠ １６３． ｃｏｍ
Ｆｕｎｄｉｎｇ ｐｒｏｇｒａｍ： Ｈｅｂｅｉ Ｍｅｄｉｃａｌ Ｓｃｉｅｎｃｅ Ｒｅｓｅａｒｃｈ Ｐｒｏｊｅｃｔ （２０１９１１１１） ； Ｂａｏｄｉｎｇ Ｓｏｃｉａｌ Ｄｅｖｅｌｏｐｍｅｎｔ Ｐｒｏｊｅｃｔｓ （１８ＺＦ２６２）

Abstract：

Objective To study the expression and clinical significance of F-box leucine-rich repeat protein 2(FBXL2) and Wnt signal pathway inhibitor 1(Dkk-1) in colorectal cancer(CRC). Methods From October 2017 to May 2019, 75 patients with CRC diagnosed and treated by general surgery in Baoding First Central Hospital were selected as the study subjects. The expression levels of FBXL2, Dkk-1 mRNA and protein in CRC carcinoma and adjacent tissues were detected by fluorescence quantitative PCR and immunohistochemistry. To compare the differences of FBXL2 and Dkk-1 protein expression in cancer tissues of CRC patients with different clinicopathological characteristics. Kaplan-Meier survival analysis(Log-rank test) The relationship between the expression of FBXL2 and Dkk-1 protein and the survival and prognosis of CRC patients. Multivariate COX regression analysis was used to analyze the risk factors affecting the survival and prognosis of CRC patients. Results The expression level of FBXL2 and Dkk-1 mRNA in CRC cancer tissue was lower than that in adjacent tissues(t=25.053, 34.053,P<0.001). The positive rate of FBXL2 and Dkk-1 protein expression in CRC cancer tissue is lower than that in adjacent tissues(χ²=58.134, 51.042,P<0.001). There was a significant positive correlation between FBXL2 and Dkk-1 protein expression in CRC cancer tissue(rs=0.714,P<0.001). The positive rates of FBXL2 and Dkk-1 protein expression in cancer tissues of patients with stageⅠto stageⅡof TNM stage and negative lymph node metastasis were higher than those of patients with stage Ⅲ of TNM stage and positive lymph node metastasis. The difference was statistically significant(χ²/P=7.588/0.006, 5.220/0.022). The 3-year cumulative survival rate of patients with negative FBXL2 expression was significantly lower than that of patients with positive FBXL2 expression(χ²=5.991,P=0.014). The 3-year cumulative survival rate of DKK-1 negative expression group was significantly lower than that of positive expression group( χ²=8.058,P=0.005). Tumor stage III, positive lymph node metastasis, negative expression of FBXL2 and negative expression of Dkk-1 were independent risk factors affecting the prognosis of CRC patients [HR(95% CI)=1.613(1.223-2.126), 1.917(1.314-2.799), 1.837(1.229-2.745), 1.738(1.246-2.426),P<0.001]. Conclusion The expression of FBXL2 and Dkk-1 in CRC cancer tissue is decreased. The expression of FBXL2 and Dkk-1 is related to the tumor stage and lymph node metastasis of CRC, and is a new tumor marker to evaluate the survival and prognosis of CRC patients.

Colorectal cancer;                    F-box leucine rich repeat protein 2;                    Wnt signal pathway inhibitor 1;                    Clinical prognosis;